The GSK share price (LSE: GSK) leapt to 1,460p today. Here’s why!

On Tuesday morning, GlaxoSmithKline (LSE: GSK) shares were limping along, opening down at 1,383p before rising to 1,390.2p at 10.50am. Then, the GSK share price suddenly took off, leaping by 70p (+4.7% on Monday’s close of 1395.2p) to hit an intra-day high of 1,460.20p. What caused the shares to suddenly jump before lunchtime? There are two possibilities.

GSK share price lifted by bid talk?

One reason for the GSK share price’s sudden rise was a story on Bloomberg business news. In this exclusive, published around 11am, the news site revealed that the UK pharma giant’s consumer healthcare division was being stalked by potential buyers. GSK plans to split itself into two distinct companies in 2022: consumer healthcare and biopharma. However, according to Bloomberg, private equity firms are “circling” the consumer healthcare arm as a potential takeover target. Other bidders might include other pharmaceutical and FMCG (fast-moving consumer goods) rivals. This may explain the GSK share price jumping earlier today.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story. In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

In what it’s describing as potentially “the biggest buyout of all time“, Bloomberg reckons the consumer arm could be valued at over £40bn ($54bn). Potential suitors include the likes of Advent International, CVC Capital Partners, and KKR. Given the sheer scale of any sale, several buyout groups could team up to make a combined bid for part of the UK’s second-largest healthcare company. Bloomberg reports that the unit’s yearly sales exceeded £10bn in 2020. But CEO Dame Emma Walmsley has been planning to split GSK into two distinct businesses for nearly three years. As things stand, the group remains on track to lists its consumer healthcare unit in London in mid-2022, nine months away. By 2.15pm, the GSK share price had dropped back to trade at 1,429.4p, up 36.6p

Stock helped by vaccine news?

An alternative explanation for the GSK share price’s quick leap could be another news report, this time on Covid-19 vaccines. The Financial Times reported that CureVac has abandoned its first vaccine. Instead, the German biotech will focus on developing a more promising new jab with partner GSK. Despite being the world’s leading supplier of vaccines, GSK has fallen behind the curve in developing effective vaccinations against the coronavirus. The FT also reported that CureVac’s phase-three trials revealed a weak 48% efficacy rate overall. Hence, the group withdrew its application to the European Medicines Agency (EMA) for regulatory approval. The second vaccine “appears to elicit 10 times more antibodies [in animal trials] than the first vaccine“, according to the FT. The partners are also working on a joint coronavirus and influenza (flu) jab.

I still own this stock

On 18 August, the GSK share price hit a 52-week high of 1,528.8p. Today, the stock is roughly £1 below that level, valuing the firm at £71bn. I own GSK shares and have done for almost 30 years. Alas, I’m kicking myself for not selling when the shares peaked in late August. But if a bidding war does erupt for consumer healthcare, then it might send the shares soaring again. If the group can get a higher price by selling the division than it could hope to by listing it, then selling may be the better option. Also, a formal auction of the unit might flush out several firm bidders. Hence, for now, I will hang onto my GSK stock and await developments!

Our #1 North American Stock For The ‘New-Age Space Race’

Billionaires like Jeff Bezos, Bill Gates, Elon Musk, and Mark Zuckerberg are already betting big money on the ‘new-age space race’, and for one very good reason…

…because this is an industry that according to Morgan Stanley could be worth $1 TRILLION by 2040.

But the problem is most of their investments are in private companies — meaning they’re largely off-limits for everyday investors.

Fortunately, our team of analysts have identified one little-known company that’s at the cutting-edge of the space industry, and is currently trading at what looks like a VERY reasonable valuation

for now.

That’s why I want to urge you to check out our premium research on this top North American space stock ASAP.

Simply click here to see find out how you can grab your copy today

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services, such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool, we believe that considering a diverse range of insights makes us better investors.

This post was originally published on Motley Fool

Financial News

Daily News on Investing, Personal Finance, Markets, and more!